Epion Therapeutics receives FDA Fast Track designation for Epithelium-Ontology Cross-Linking System

Series B rounds abound with Kardigan raising $254M and Kailera Therapeutics pulling in $600M. Kardigan is advancing three cardiovascular assets into late-stage clinical trials, while Kailera is focused on its obesity pipeline and global phase III efforts. The financings represent the top two series B rounds of biopharma companies in 2025.   Read Karen Carey’s report in BioWorld News: https://lnkd.in/ecnnpWCm (Access this exclusive content with a Premium BioWorld subscription: https://lnkd.in/ex_sZAtE) #biopharma #cardiovascular #obesity Clarivate for Life Sciences & Healthcare

🩸 A breakthrough for blood pressure treatment could be on the way - a University of Aberdeen pre-spinout company will take the next 'crucial' step towards bringing a brand-new type of blood pressure medication to patients thanks to a funding award from the Scottish Funding Council. The £125k award from the ‘Proof of Concept’ scheme will see the University-led drug development pre-spinout group DIOKA Therapeutics test whether their revolutionary new idea will work beyond the cellular level that has already proven more successful than they could have imagined. Read more ➡️ http://abdn.io/1KE

Managing pediatric Atopic Dermatitis (AD) today involves more than treating flares. Clinicians can optimize outcomes by combining foundational care, such as consistent moisturization, with emerging options like JAK inhibitors and biologics. Learn how experts are rethinking the AD journey through early intervention and patient-centered strategies in our latest blog post. 🔗 https://lnkd.in/eJ2rV8bQ #AtopicDermatitis #PediatricAtopicDermatitis #Eczema #LiVDerm

📣 Exciting news from Atom Therapeutics! We’re proud to announce that we’ll be presenting positive clinical trial data for our novel oral drug candidates targeting chronic gout and acute gout flares at ACR Convergence 2025. Stay tuned for more details as we continue advancing innovative treatments for patients living with gout. Read the complete press release here: https://lnkd.in/ggMjmSk8 #ACR2025 #Gout #ClinicalResearch #Innovation #AtomTherapeutics

Star Therapeutics just banked a $125M Series D to push its bleeding disorder candidate into Phase 3 — betting the space could be pharma’s next big frontier. https://lnkd.in/gRsQ8Fsp

Stifel is pleased to share the latest Biopharma Market Report, highlighting key industry developments, an overview of capital markets and deal activity, and the latest progress in RNA Therapeutics. Click here to learn more: https://lnkd.in/e_ZZEc6u #biopharma #RNATherapeutics #primarycare #preventativemedicine #healthcare #investmentbanking

🚀 We’re excited to share that Crystalys Therapeutics has officially launched with a $205 million Series A financing to help transform care for people living with gout, a condition that continues to have high unmet medical need. This funding will accelerate our global Phase 3 clinical program for our lead candidate, dotinurad, a next-generation, once-daily oral URAT1 inhibitor. Designed with the potential to set a new standard in both safety and efficacy, dotinurad aims to bring a much-needed best-in-class option to patients and physicians. For more details: https://prn.to/42X3n0R For more about Crystalys: https://crystalystx.com/

Exciting news for Fortress Biotech's private subsidiary Urica Therapeutics, Inc., which contributed the rights to this drug candidate, dontinurad, to Crystalys in exchange for equity in the venture. Dotinurad a once-daily pill targeting one of the two ways that uric acid is elevated—known as hyperuricemia—which leads to gout, was approved in Japan for treatment of hyperuricemia in 2020. Another great example of the innovative approach Fortress takes to finding drug candidates with favorable risk profiles and advancing them effectively using industry collaboration, and a proven track record.

We are thrilled to welcome Crystalys Therapeutics to the Lightstone Ventures portfolio, and partnering to address the unmet medical needs for patients living with #gout. Full press release: https://prn.to/42X3n0R

Interest in radioligand therapy (RLT) continues to accelerate. An analysis of PubMed data from 2000–2024 shows a clear upward trend in publications on clinical therapeutic radionuclides—evidence of both increasing innovation and growing clinical focus on systematic radioligand therapy (SRT). What does this momentum mean for the future of radiotheranostics? We explore the implications in a recent blog, drawing on data from Radiotheranostic landscape: A review of clinical and preclinical development (Tran et al., 2025). Read more here: https://lnkd.in/eraa8PNd #RadioligandTherapy #SRT #Radiopharmaceuticals #LifeSci #Bracken